XTX Topco’s Alzamend Neuro ALZN Stock Holding History

XTX Topco’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,470	Closed	-$22.7K	–	3799
2025 Q4	$22.7K	Buy	+12,470	New	+$28.3K	﹤0.01%	3030
2023 Q4	–	Sell	-10	Closed	-$3.08K	–	1547
2023 Q3	$3.08K	Buy	+10	New	+$4.78K	﹤0.01%	1481
2022 Q1	–	Sell	-8	Closed	-$21K	–	655
2021 Q4	$21K	Buy	+8	New	+$24.8K	0.01%	624

Other funds holding ALZN

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

XTX Topco's ALZN Position: Q1 2026 in Review

XTX Topco sold out of Alzamend Neuro (ALZN) in Q1 2026, closing a stake of 12,470 shares — an estimated $22.7K sold.

XTX Topco first reported a position in ALZN in Q4 2021 and held it in 3 quarters. The position peaked at $22.7K in Q4 2025. 12 funds tracked by Wall St. Rank hold ALZN as of Q1 2026.

XTX Topco reported no remaining Alzamend Neuro position as of Q1 2026 after selling out during the quarter.
XTX Topco sold 12,470 Alzamend Neuro shares in Q1 2026, an estimated $22.7K.
XTX Topco first reported a position in Alzamend Neuro in Q4 2021 and held it in 3 quarters.
XTX Topco's Alzamend Neuro position peaked at $22.7K in Q4 2025.
12 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.